13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001643354
Total reported value
$20.9M
$20.9M
19 檔
46.2%
In Q4 2024, Lion Point Capital, LP's U.S. equity holdings reached a combined market value of $20.9M, distributed across 19 disclosed stock positions.
In Q4 2024, Lion Point Capital, LP adopted a defensive or profit-taking posture, trimming 8 positions and completely liquidating 7 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | Stock-Healthcare | 13.27% | — | -29.69% | |
| 2 | MIST | Milestone Pharmaceuticals In | Stock-Other | 12.68% | -0.57% | -37.99% | |
| 3 | GERN | Geron CORP | Stock-Other | 9.27% | -1.61% | -20.63% | |
| 4 | ARDX | Ardelyx Inc | Stock-Other | 8.90% | -1.47% | -9.35% | |
| 5 | FENC | Fennec Pharmaceuticals Inc | Stock-Other | 6.48% | +1.65% | -8.98% | |
| 6 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 5.79% | -0.44% | -17.76% | |
| 7 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 5.09% | -0.34% | — | |
| 8 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 4.75% | — | -25.24% | |
| 9 | BHVN | Biohaven Ltd. | Stock-Other | 4.44% | +1.07% | -35.88% | |
| 10 | BNTC | Benitec Biopharma Inc | Stock-Other | 4.10% | +0.02% | +58.97% | |
| 11 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 3.81% | -1.27% | +19.05% | |
| 12 | JSPR | Jasper Therapeutics Inc | Stock-Other | 3.58% | -1.50% | — | |
| 13 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 3.52% | — | — | |
| 14 | IRON | Disc Medicine Inc | Stock-Other | 3.52% | -0.27% | +37.66% | |
| 15 | BLE0 | Bluebird Bio Inc | Stock-Other | 3.45% | — | — | |
| 16 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 3.38% | -0.08% | +31.91% | |
| 17 | RGNX | Regenxbio Inc | Stock-Other | 2.34% | +0.19% | — | |
| 18 | MCRB1EUR | Seres Therapeutics Inc | Stock-Other | 1.48% | — | — | |
| 19 | SPRU | Spruce Power Holding Corporation | Stock-Other | 0.16% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MIST | Milestone Pharmaceuticals In | +7.1% | -37.99% | Trim |
| 2 | INSM | Insmed Inc | +4.8% | -29.69% | Trim |
| 3 | FENC | Fennec Pharmaceuticals Inc | +4.1% | -8.98% | Trim |
| 4 | BLE0 | Bluebird Bio Inc | +3.5% | NEW | New buy |
| 5 | BNTC | Benitec Biopharma Inc | +3.3% | +58.97% | Add |
| 6 | ARDX | Ardelyx Inc | +3.2% | -9.35% | Trim |
| 7 | BBIO | Bridgebio Pharma Inc | +3% | -17.76% | Trim |
| 8 | MLYS | Mineralys Therapeutics Inc | +3% | — | Unchanged |
| 9 | GERN | Geron CORP | +2.9% | -20.63% | Trim |
| 10 | IRON | Disc Medicine Inc | +2.7% | +37.66% | Add |
| 11 | ARQT | Arcutis Biotherapeutics Inc | +2.7% | +31.91% | Add |
| 12 | JSPR | Jasper Therapeutics Inc | +2.2% | — | Unchanged |
| 13 | SNDX | Syndax Pharmaceuticals Inc | +1.8% | +19.05% | Add |
| 14 | ✓ | Avadel Pharmaceuticals PLC ADR | +1.7% | — | Unchanged |
| 15 | KNSA | Kiniksa Pharmaceuticals International, plc | +1.3% | -25.24% | Trim |
| 16 | RGNX | Regenxbio Inc | +1% | — | Unchanged |
| 17 | MCRB1EUR | Seres Therapeutics Inc | +0.8% | — | Unchanged |
| 18 | BHVN | Biohaven Ltd. | +0.5% | -35.88% | Trim |
| 19 | SPRU | Spruce Power Holding Corporation | +0.1% | — | Unchanged |
| 20 | GOOG | Alphabet Inc-cl C | 0% | EXIT | Sold out |
| 21 | MSFT | Microsoft CORP | -0.1% | EXIT | Sold out |
| 22 | 4NX1 | Lumos Pharma Inc | -0.3% | EXIT | Sold out |
| 23 | ✓ | -1.8% | EXIT | Sold out | |
| 24 | MRNS* | Marinus Pharmaceuticals Inc | -2.7% | EXIT | Sold out |
| 25 | MIRM | Mirum Pharmaceuticals Inc | -3.9% | EXIT | Sold out |
| 26 | IWM | Ishares Russell 2000 ETF | -40.6% | EXIT | Sold out |
According to official SEC Form 13F filings, Lion Point Capital, LP reported a total U.S. public equity portfolio value of $20.9M across 19 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including INSM, MIST, GERN) accounted for 46.2% of total reported equity market value during Q4 2024.
Top New Position Initiated
BLE0
市值: $658.1K
Top Position Liquidated / Trimmed
IWM
前期市值: $18.2M
During Q4 2024, Lion Point Capital, LP's top holdings by market value included INSM (13.3%)、MIST (12.7%)、GERN (9.3%). The largest single position, INSM, represented 13.3% of total portfolio value.
In Q4 2024, Lion Point Capital, LP made 20 total portfolio adjustments, initiating 1 new buys, adding to 4 positions, trimming 8 holdings, and fully liquidating 7 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.